Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants

• Published in: Journal of clinical pharmacology Vol. 52; no. 6; p. 904
• Main Authors: Willis, Brian A, Zhang, Wei, Ayan-Oshodi, Mosun, Lowe, Stephen L, Annes, William F, Sirois, Paul J, Friedrich, Stuart, de la Peña, Amparo
• Format: Journal Article
• Language: English
• Published: England 01.06.2012
• Subjects: Aged; Alanine - administration & dosage; Alanine - analogs & derivatives; Alanine - blood; Alanine - pharmacokinetics; Alanine - pharmacology; Amyloid beta-Peptides - blood; Amyloid Precursor Protein Secretases - antagonists & inhibitors; Azepines - administration & dosage; Azepines - blood; Azepines - pharmacokinetics; Azepines - pharmacology; Biological Availability; Capsules; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Administration Schedule; Female; Food-Drug Interactions; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nootropic Agents - administration & dosage; Nootropic Agents - blood; Nootropic Agents - pharmacokinetics; Nootropic Agents - pharmacology; Patient Dropouts; Peptide Fragments - blood; Tablets

Semagacestat, a γ-secretase inhibitor, reduces formation of amyloid beta peptide. Two single-dose (140 mg), open-label, randomized, 3-period, crossover studies evaluated the effect of formulation, food, and time of dosing on the pharmacokinetics and pharmacodynamics of semagacestat in healthy partic...